Literature DB >> 10024690

Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells.

Y Kirihara1, W Yamamoto, T Toge, M Nishiyama.   

Abstract

Gene expression of dihydropyrimidine dehydrogenase (DPD) and newly multidrug resistance-associated protein (MRP) was found to correlate well with primary 5-FU resistance in 7 human gastrointestinal cancer cell lines. Although mRNA and protein levels of thymidylate synthase (TS) did not relate to the resistance, 5-FU treatment revealed a remarkable increase of TS expression. Such enhanced TS expression was more significant than DPD and MRP, and observed less in 5-FU sensitive cells. DPD and MRP expression levels can predict primary 5-FU resistance, and TS may be a potent predictor of cellular 5-FU resistance after 5-FU treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024690     DOI: 10.3892/ijo.14.3.551

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.

Authors:  Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

3.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

4.  Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy.

Authors:  Björn L D M Brücher; Gisela Keller; Martin Werner; Ulrike Müller; Silke Lassmann; Antonello Domenico Cabras; Falko Fend; Raymonde Busch; Hubert Stein; Hans-Dieter Allescher; Michael Molls; J Rüdiger Siewert; Heinz Höfler; Katja Specht
Journal:  Int J Colorectal Dis       Date:  2008-08-13       Impact factor: 2.571

5.  Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.

Authors:  Hiroya Takiuchi; Shin-Ichiro Kawabe; Masahiro Gotoh; Ken-Ichi Katsu
Journal:  Gastrointest Cancer Res       Date:  2007-09

6.  DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.

Authors:  M Wasif Saif; Kostas Syrigos; Ranee Mehra; Lori K Mattison; Robert B Diasio
Journal:  Pak J Med Sci       Date:  2007       Impact factor: 1.088

7.  Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.

Authors:  Eiji Sasaki; Kazunari Tominaga; Hikaru Kuwamura; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Kazuhide Higuchi; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

Review 8.  Challenge for a better combination with basic evidence.

Authors:  Kazuhiro Yoshida; Kazuya Yamaguchi; Shinji Osada; Yoshihiro Kawaguchi; Takao Takahashi; Fumio Sakashita; Yoshihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

9.  Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.

Authors:  J F Mirjolet; M Barberi-Heyob; C Didelot; J P Peyrat; J Abecassis; R Millon; J L Merlin
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.

Authors:  C Martínez; E García-Martín; R M Pizarro; F J García-Gamito; J A G Agúndez
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.